The goal of this clinical trial is to learn if caffeine citrate prevents apneic events that result in sick visits in moderately preterm infants after discharge from the hospital. It will also learn if the use of caffeine leads to better developmental outcomes at 12 months of age.
Our research questions are:
1. Does continued treatment of moderately preterm newborns with caffeine citrate after hospital discharge prevent or decrease apneic events that result in sick visits?
2. Will the continued use of caffeine citrate lead to improved developmental outcomes among infants at 12 months of age?
Researchers will compare caffeine citrate to a placebo (a look-alike substance that contains no drug) to see if caffeine citrate prevents apneic spells which result in healthcare visits.
Parents of participants will:
1. Administer caffeine citrate 20mg/kg/day or a placebo (equivalent volume of sterile water) orally every day for up to 28 days after hospital discharge
2. Keep a diary of symptoms and any apneic events
3. Check in with researchers via telephone call once a week
4. Return to clinic for infant physical examination at 28 days
5. Return to the clinic for infant physical examination at 2 months
5. Return to clinic for infant neurodevelopmental examination with Ages and Stages Questionnaire at 12 months of age

开始日期2026-01-01

申办/合作机构

The University of Alabama at Birmingham

[+1]

NCT06972108

/ Not yet recruiting临床2期IIT

Caffeine for Oxygen Dependent Meconium Aspiration Syndrome

When babies are stressed in the womb, they sometimes pass meconium in the amniotic fluid. When this happens, they may swallow the meconium-stained fluid into their lungs which may cause them to have poor oxygen levels and require resuscitation and significant breathing support in the early hours after birth. This is referred to as Meconium Aspiration Syndrome (MAS). Some babies may recover slowly and require breathing and/or oxygen support for days. Caffeine is a drug that can help improve breathing efforts and is commonly used in premature babies who do not have regular or strong breathing efforts. Caffeine has been used in babies with MAS who recovered slowly (i.e. requiring breathing or oxygen support for a longer period) for several years now. Despite having success in many babies, there is no evidence to examine its effectiveness and mechanism of action. This pilot study proposes to look at the effects of caffeine in babies with MAS who require ongoing breathing and oxygen support. There will also be examination of whether caffeine improves breathing efforts with better lung opening using ultrasound images of the lungs.

开始日期2025-12-01

申办/合作机构

University of Alberta

100 项与枸橼酸咖啡因相关的临床结果

登录后查看更多信息

100 项与枸橼酸咖啡因相关的转化医学

登录后查看更多信息

100 项与枸橼酸咖啡因相关的专利（医药）

登录后查看更多信息

30,497

项与枸橼酸咖啡因相关的文献（医药）

2026-02-01·NEUROPHARMACOLOGY

Caffeine Citrate does not reduce brain injury following inflammation-amplified hypoxia ischaemia or hypoxia ischaemia in the Newborn Piglet Model

Article

作者: Bainbridge, Alan ; Norris, Georgina ; Campbell, Ellie ; Robertson, Nicola J ; Pang, Raymand ; Tucker, Katie ; Torrealdea, Francisco ; Barks, John ; Tsuda, Kennosuke ; Meehan, Christopher ; Mintoft, Alison ; Kim, Yujin ; Han, Louise ; d'Angelo, Ilenia ; Maple, George

There is a need to develop alternative therapies for neonatal encephalopathy (NE) in term babies. Caffeine citrate exposure saw benefit in preclinical models of hypoxia-ischaemia (HI). We assessed the safety and cytoprotective efficacy of caffeine citrate in an inflammation-amplified (IA-HI) and HI newborn piglet model based on the probability of treatment superiority (Pr_(sup)) of magnetic resonance spectroscopy, amplitude integrated encephalography (aEEG/EEG) and immunohistochemistry outcomes. Eighteen newborn piglets were randomised to saline, 20/10/10 mg/kg or 60/30/30 mg/kg caffeine citrate following IA-HI. A further twenty piglets were randomised to saline or 40/10/10 mg/kg caffeine citrate following HI. Caffeine plasma concentrations were within range following a 20/10/10 mg/kg dosage but were lower than putative target levels following a 40/10/10 mg/kg dosage. Caffeine concentrations exceeded toxic levels following a 60/30/30 mg/kg dosage. Following IA-HI, 20/10/10 or 60/30/30 mg/kg caffeine citrate treatment failed to reduce white matter (WM) (Pr_(sup) 39.3 %, 52.5 %) and basal ganglia and thalamic (BGT) (Pr_(sup) 35.0 %, 50.3 %) lactate/N-acetylaspartate (Lac/NAA), preserve the phosphocreatine/exchange phosphate pool (PCr/Epp) ratio (Pr_(sup) 44.2 %, 62.0 %), or improve aEEG/EEG recovery (Pr_(sup) 22.4 %, 21.7 %). A 60/30/30 mg/kg dose demonstrated increased cell death, indicating toxicity. Following HI, 40/10/10 mg/kg caffeine citrate treatment failed to reduce WM (Pr_(sup) 58.3 %) and BGT (Pr_(sup) 48.0 %) Lac/NAA, preserve the PCr/Epp ratio (Pr_(sup) 72.8 %), or improve aEEG/EEG recovery (Pr_(sup) 48.0 %), with seizures more refractory. However, there was a modest benefit in male caffeine-treated piglets following HI. The lack of neuroprotection observed following caffeine citrate treatment after both IA-HI and HI suggests further preclinical studies are required before clinical translation for term babies with NE.

2026-01-01·Ophthalmology science

Caffeine Therapy Reduces Severe Retinopathy of Prematurity in Neonates with Gestational Age between 23 and 28 Weeks

Article

作者: Taketani, Futoshi ; Otsuka, Yuki ; Oh, Hideyasu ; Hirose, Miou

Purpose:

To investigate the association of caffeine citrate therapy with the onset and exacerbation of retinopathy of prematurity (ROP).

Design:

A retrospective observational cohort study.

Participants:

Preterm neonates born at Hyogo Prefectural Amagasaki General Medical Center between January 2018 and December 2023 were included.

Methods:

Data on maternal (age; comorbid hypertensive disorders of pregnancy and gestational diabetes mellitus; fetal growth restriction; and cesarean section) and neonatal (sex; gestational age; birth weight; zone at initial examination; Apgar scores; respiratory distress syndrome; chronic lung disease; tracheal intubation; duration of tracheal intubation; duration of oxygen therapy; and caffeine therapy) risk factors for ROP were collected from medical records.

Main Outcome Measures:

Retinopathy of prematurity onset and severe ROP were defined as stage ≥1 and stage ≥3 during the course of follow-up, respectively. The association between caffeine therapy and the onset of any ROP and severe ROP was investigated.

Results:

Among 202 neonates included in the current study, 94 (46.5%) developed any ROP (stage ≥1) during the observational period. Only the zone at initial examination affected the onset of any ROP (P < 0.01). However, in 115 neonates born at <32 weeks gestational age and with <1500 g birth weight, larger zones at baseline and caffeine treatment were associated with decreased severe ROP (P = 0.017 and P < 0.01, respectively). Additionally, in 54 neonates with gestational age between 23 and 28 weeks, only caffeine therapy was associated with decreased development of severe ROP (P < 0.01). All 4 neonates with gestational age <23 weeks progressed to severe ROP despite caffeine therapy.

Conclusions:

Caffeine therapy may be a potential treatment strategy to prevent the progression of severe ROP in neonates born between 23 and 28 weeks' gestational age.

Financial Disclosures:

The authors have no proprietary or commercial interest in any materials discussed in this article.

2025-12-31·Journal of the International Society of Sports Nutrition

Caffeine supplementation improved movement patterns and reactive agility in rugby sevens matches in male collegiate players

Article

作者: Hsueh, Chang-Li ; Sun, Cheng-Yen ; Chang, Chen-Kang

PURPOSE:

Rugby sevens is a high-intensity contact sport often played in two-day tournaments. Caffeine is widely used by rugby players for its performance-enhancing effects. This study aimed to investigate the impact of caffeine supplementation on various performance metrics, including distance covered at different speeds, acceleration, deceleration, collisions, and repeated high-intensity efforts across four matches over two consecutive days in collegiate male rugby sevens players. Reactive agility, a key performance attribute in rugby sevens, was also assessed before each match.

METHODS:

A position-matched, double-blind, randomized crossover design was employed, with six male collegiate rugby players (mean height: 1.78 ± 0.09 m, mean weight: 81.3 ± 9.2 kg, mean age: 21.5 ± 0.8 years) participating in two trials. Each trial consisted of a two-day tournament, with two matches per day. Performance was monitored using global positioning system units to track distance covered in various speed zones, as well as total distance, frequency of acceleration, deceleration, collisions, and repeated high-intensity efforts.

RESULTS:

The results indicated that in the placebo trial, participants covered significantly more distance at a walking pace (0-6 km/h) in match 4 compared to match 3 (match 3: 480.3 ± 32.7 m; match 4: 629.4 ± 21.3 m, p < 0.001, d = 0.117). In the caffeine trial, players covered significantly more distance at a jogging pace (6-12 km/h) in match 4 compared to the placebo trial (caffeine: 405.9 ± 9.8 m; placebo: 303.6 ± 20.2 m, p = 0.015, d = 1.693). Reactive agility was significantly better in the caffeine trial before match 3 (caffeine trial: 1.80 ± 0.17 s; placebo trial: 2.07 ± 0.18 s, p = 0.038, d = 0.858).

CONCLUSIONS:

Caffeine supplementation at 3 mg/kg may increase jogging and reduce walking and standing in the final match of a two-day rugby sevens tournament, while also improving reactive agility on the second day. This suggests that by mitigating fatigue in the later stages of the tournament, caffeine allowed players to shift from low-intensity activities to higher-intensity efforts. These adjustments may improve both offensive and defensive performance during rugby sevens matches. Therefore, rugby sevens players could benefit from taking caffeine supplements in the later stages of 2-day tournaments to optimize their performance.

190

项与枸橼酸咖啡因相关的新闻（医药）

2025-11-19

·有驾

石药尼达尼布首仿申报与医药行业新动态解析

◇ 石药尼达尼布首仿申报石药集团恩必普药业近日率先提交了三联血管激酶抑制剂尼达尼布软胶囊的仿制药申请，旨在抢占市场先机。该药按新4类仿制药申报，一旦获批，将视同通过一致性评价，为患者提供更多治疗选择。尼达尼布的原研药是勃林格殷格翰的乙磺酸尼达尼布（Nintedanib Esylate，Ofev®），自2014年10月获FDA批准用于治疗特发性肺纤维化（IPF）患者以来，已广泛应用于临床。2015年7月，尼达尼布被ATS/ERS/JRS/ALAT特发性肺纤维化诊治国际循证指南推荐为首选用药，进一步巩固了其市场地位。2017年9月，该药获准进口中国，为国内患者带来了福音。近年来，尼达尼布的原研药销售额持续攀升，2018年度销售额达到11亿欧元，同比增长28.7%，显示出其强大的市场潜力。 ◇ 豪森药业新药上市豪森自主研发的长效GLP-1受体激动剂聚乙二醇洛塞那肽注射液（商品名：孚来美）已获国家药监局批准，该药每周仅需注射一次，能有效改善2型糖尿病成人患者的血糖控制情况。值得注意的是，这款药物是首款由国内企业自主研发并获得批准的长效GLP-1制剂，其降糖效果显著且低血糖风险较低。 ◇ 太极集团药物受理太极集团西南药业所研发的枸橼酸咖啡因注射液已获国家药监局受理，拟用于治疗早产新生儿原发性呼吸暂停。该药在欧美地区已广泛用于临床治疗早产儿呼吸暂停，并被世界卫生组织核心基本药物标准目录及儿童基本药物标准目录收录。 ◇ 诺华药物审评进展国家药监局药品审评中心公示，诺华开发的西尼莫德片拟纳入优先审评名单。西尼莫德片作为新一代选择性1-磷酸鞘氨醇（S1P）受体调节剂，能够通过与淋巴细胞中的S1P1亚型受体结合，阻止其进入多发性硬化症患者中枢神经系统，从而发挥抗炎作用。今年3月，该药已获FDA批准用于治疗复发型多发性硬化症成年患者。 ◇ 康乃德生物临床结果康乃德生物新型IL-4Rα抗体CBP-201在临床Ⅰa期单剂量递增试验中表现出色。试验结果显示，受试者在接受皮下或静脉注射CBP-201后，血液中胸腺激活和调节趋化因子水平显著降低。此外，皮下注射600mg剂量的生物利用度高达89％，且在第56天时受试者血液中CBP-201的浓度远高于在人外周血单核细胞中实现完全阻断IL-4Rα的药物浓度。 ◇ 康弘药业临床获批康弘药业子公司康弘生物的康柏西普眼用注射液已获国家药监局批准，即将在新生血管性（湿性）年龄相关性黄斑变性患者中开展国际多中心III期临床试验。该药物是康弘生物自主研发的1类生物创新药，能有效结合血管及组织中的VEGF，阻断其介导的新生血管出芽和生长信号传递。 ◇ Ionis新药欧盟获批 Ionis公司与Akcea子公司共同开发的反义寡核苷酸药物Waylivra，获欧盟委员会批准，用于治疗家族性乳糜微粒血症综合征（FCS）成年患者。这是欧盟首个获批的FCS治疗药物，全球范围内也属首例。在Ⅲ期APPROACH试验中，Waylivra显著降低了患者甘油三酯水平，并减少了胰腺炎发作。 ◇ Circassia新药获批 Circassia公司与阿斯利康联合开发的Duaklir，获FDA批准用于治疗慢性阻塞性肺病（COPD）。该药物为固定剂量组合，包含长效毒蕈碱拮抗剂和长效β-激动剂，每日两次通过吸入器给药。临床数据显示，该疗法可有效减轻COPD恶化。 ◇ Viela Bio临床终点 Viela Bio公司的抗CD19单克隆抗体inebilizumab，在治疗视神经脊髓炎谱系疾病（NMOSD）的Ⅲ期临床N-Momentum中达到主要终点和关键性次要终点。结果显示，inebilizumab显著降低了NMOSD发作风险，并改善了患者预后。 ◇ 基因泰克SMA疗法结果基因泰克等联合开发的口服SMN2 RNA剪接调节剂risdiplam，在两项临床试验中获得积极结果。该药物可改善1型脊髓性肌肉萎缩症（SMA）患者的症状，并有望用于治疗2型和3型SMA患者。 ◇ 阿斯利康BTK抑制剂阿斯利康的布鲁顿氏酪氨酸激酶（BTK）抑制剂Calquence，在治疗复发/难治性慢性淋巴性白血病（R/R CLL）患者的Ⅲ期临床ASCEND中达到主要终点指标。与对照组相比，Calquence单药疗法显著改善了患者的无进展生存期。 ◇ 默沙东失眠药物研究默沙东的失眠药物Belsomra（suvorexant），用于轻中度阿尔茨海默症（AD）患者失眠治疗的III期临床达到主要终点指标。与安慰剂相比，Belsomra显著增加了患者的总睡眠时间（TST）。 ◇ 上海公立医院新规上海市卫健委最近印发的《上海市公立医疗机构门诊医师出诊管理办法（试行）》明确了这一规定。该《办法》强调，医疗机构必须根据专业特点来核定医师出诊单元的工作量，并对加号进行严格管理。对于号源已满的专病、专科、专家或特需门诊，预约就诊者需先进行实名制身份认定，并经医师书面同意或医生工作站电子认可后，方可进行加号预约挂号。同时，医疗机构需对医师加号的依据、时段和比例进行严格控制，确保加号号源不超过核定号源的20%，从而保障诊疗时间和质量。 ◇ 国际医疗队认证世界卫生组织专家团队近期对天津市人民医院进行了实地考察，并评估认证了该院的国际应急医疗队为我国第4支国际应急医疗队。这支医疗队自2010年成立以来，不断汲取国际先进卫生应急管理经验，完善队伍建制、医疗救援程序和物资保障等工作机制，已具备随时待命参与国内外紧急医学救援工作的能力。 ◇ 台湾细胞治疗批准备台湾卫生主管部门近日批准了一家医院开展自体免疫细胞治疗，这是台湾首家获此批准的医院。该医院首个获批临床应用的细胞类型为自体免疫细胞（CIK），主要适用于血液恶性肿瘤经标准治疗无效的患者。 ◇ 医药板块走势昨日A股医药板块整体下跌0.81%，其中涨幅前三的是四环生物（+10.06%），而跌幅前三的是康美药业（-9.96%）。龙津药业上涨10.00%，海南海药下跌9.95%；瑞普生物上涨10.00%，华润三九下跌9.67%。此外，恒瑞医药旗下子公司瑞石生物医药有限公司收到国家药品监督管理局的《临床试验通知书》，获准开展SHR0302片的II期临床试验。同时，华仁药业也公布了重大股权转让进展，将向西安曲江文化金融控股有限公司或其成立的主体转让236,442,597股股份，占总股本的20%，预计将导致公司实际控制人变更为西安曲江新区管理委员会。另外，东北制药近期进行了高层人事变动，汲涌先生和张利东先生分别辞去总经理和董事会秘书职务，同时聘任了新任总经理周凯先生和副总经理季光辉先生，并聘任蔡洋先生为公司新任董事会秘书。

2025-11-10

·Science Daily

Surprising heart study finds daily coffee may cut AFib risk by 39%

New research finds that daily coffee drinking may cut AFib risk by nearly 40%, defying decades of medical caution. Scientists discovered that caffeine’s effects on activity, blood pressure, and inflammation could all contribute to a healthier heart rhythm. The DECAF clinical trial’s findings suggest coffee could be not only safe but beneficial for people with A-Fib. New research suggests that drinking coffee may actually help protect against atrial fibrillation (AFib), a common heart rhythm disorder that causes the heart to beat too quickly and irregularly, sometimes leading to stroke or heart failure. For years, doctors have advised people with AFib and other heart issues to stay away from caffeine, fearing it could worsen symptoms. But a new study from UC San Francisco and the University of Adelaide has found the opposite: participants who drank one cup of caffeinated coffee a day had a 39% lower risk of developing AFib. Why Coffee May Help the Heart "Coffee increases physical activity which is known to reduce atrial fibrillation," explained Gregory M. Marcus, MD, MAS, an electrophysiologist at UCSF Health and the senior author of the study, published November 9 in JAMA. Marcus added that "caffeine is also a diuretic, which could potentially reduce blood pressure and in turn lessen AFib risk. Several other ingredients in coffee also have anti-inflammatory properties that could have positive effects." Rates of AFib have been climbing in recent years, largely due to aging populations and increasing obesity. More than 10 million adults in the United States have been diagnosed, and experts estimate that as many as one in three people may experience the condition at some point in their lives. Testing Coffee's Effect on Heart Rhythm To explore whether coffee helps or harms, researchers designed the DECAF study (Does Eliminating Coffee Avoid Fibrillation?), the first randomized clinical trial to test the relationship between caffeinated coffee and AFib. The project was funded by the National Institutes of Health. The trial involved 200 patients who were regular coffee drinkers and had persistent AFib or a related condition known as atrial flutter, along with a history of AFib. All were scheduled to undergo electrical cardioversion, a procedure that uses a controlled electrical shock to restore normal heart rhythm. Participants were randomly assigned to either drink at least one cup of caffeinated coffee or an espresso shot each day, or to completely avoid coffee and other caffeinated beverages for six months. Coffee Drinkers Had Lower Risk At the end of the study, the group that drank coffee experienced a 39% lower risk of recurring AFib episodes. In addition to coffee's potential anti-inflammatory effects, the researchers proposed that those who drank coffee may have naturally replaced less healthy drinks, such as sugary sodas, with coffee instead. "The results were astounding," said first author Christopher X. Wong, PhD, of UCSF, the University of Adelaide, and the Royal Adelaide Hospital. "Doctors have always recommended that patients with problematic AFib minimize their coffee intake, but this trial suggests that coffee is not only safe but likely to be protective." Authors from UCSF include Gabrielle Montenegro; Hannah H. Oo; Isabella J. Pena; Janet J. Tang, PhD; Grace Wall; Thomas A. Dewland, MD; Joshua D. Moss, MD; Edward P. Gerstenfeld, MD; Zian H. Tseng, MD; Henry H. Hsia, MD; Randall J. Lee, MD, PhD; Jeffrey E. Olgin, MD; Vasanth Vedantham, MD; Melvin M. Scheinman, MD; and Catherine Lee, PhD. Marcus is supported by R01 HL158825-01, R01 HL167975-01, R01 DA058069-01, and R01 HL159069-01A1 grants from the National Heart, Lung and Blood Institute, as well as R01 AA022222 from the National Institute on Alcohol Abuse and Alcoholism.

临床结果

2025-11-08

·梅斯医学

经常喝肺癌风险飙升54%？多项研究：每天多喝一杯肺癌风险增6%；每天3杯，男性膀胱癌风险猛涨79%

一代人有一代人的精神寄托，如果说现代人，尤其是忙碌的打工人需要寄托些什么，那八成是「咖啡」。早晨灌进这么一杯，大脑瞬间清醒，连灵魂都速速归位了。之前看到一个段子，说「咖啡不能解决问题，但没咖啡，我连问题都不想面对」。确实，「续命水」的称号可不是白来的。咖啡因水平高，肺癌风险升高54% 但喝着喝着，看到几项新的研究把咖啡和癌症扯上了关系。打工人表示天都塌了…… 来自哈尔滨医科大学附属肿瘤医院的研究团队发表于European Journal of Nutrition的一项研究[1]表明，长期血浆咖啡因水平较高的人，肺癌风险竟增加了54%。更大规模的综合分析结果也同样让人咋舌。这就纳了闷了，咖啡因到底是怎么和癌症「勾结」到一块去的？研究者进一步指出，一方面，咖啡因可能削弱抗氧化系统，使细胞更容易受到氧化应激和DNA损伤，从而增加癌变风险。另一方面，咖啡因还是ATM激酶的抑制剂。ATM激酶是细胞应对DNA损伤的重要信号分子。一旦DNA受损，ATM就会启动p53通路，引导受损细胞“自我毁灭”。然而，咖啡因抑制了ATM活性，p53的作用就无法正常发挥，异常细胞可能逃脱清除，于是就这样一步步演化成了肿瘤细胞。每多喝一杯，肺癌风险升高6% 此时，不少人已经开始犯嘀咕了：这又是基因位点，又是MR分析的，要检测血浆咖啡因水平可太难了。不如直接来个「痛快」的，每天到底喝多少咖啡才是危险的？此前，一项发表于Nature子刊 Scientific Reports的研究[2]倒是提供了一种「具体」的参考。这项研究表明，咖啡摄入量与肺癌风险之间存在显著正相关。与不喝咖啡的人群相比，常规饮用咖啡者罹患肺癌的风险上升了28％。不仅如此，研究团队还进一步进行了剂量反应分析。他们发现，随着每天咖啡摄入量的增加，肺癌的风险也呈现出线性上升的趋势。这下是真把人整不会了……如果盛情难却的同事A上午请我喝一杯咖啡，另一盛情难却的同事B下午又请我喝一杯咖啡，何解？（同事们，都明白了吧）这咖啡怎么就和肺癌绑住了呢？原来，这次「为非作歹」的是丙烯酰胺。它是一种具有遗传毒性的化合物，在动物实验中已被证实能够损伤DNA、诱发氧化应激反应，进而诱导癌细胞形成。很不巧，咖啡豆在烘焙过程中，糖类与氨基酸发生美拉德反应，会大量生成这种潜在致癌物质。喝「脱因」版也不安全但不管怎么说，总有些人几杯咖啡下肚后，心悸不适，彻夜难眠。这些人平时喝咖啡只选「脱因」版，只是为了尝尝这股子咖啡香气和口感。但「脱因咖啡」就不会受到癌症的「青睐」了吗？非也非也！哈佛大学公共卫生学院的研究团队发表于Annals of Oncology的一项研究[3]就再次扎心了：在从不吸烟的男性中，喝脱咖啡因咖啡与膀胱癌风险升高显著相关。不过，这种关联仅出现在男性身上，在女性中没有观察到相似风险。（1杯约240ml）至于研究结果，可以说是「雪上加霜」了。接下来，研究人员剔除了「吸烟」这一混杂因素，结果却更扎眼了。不管带不带咖啡因，癌症怎么都像「狗皮膏药」一样甩都甩不掉呢？这次「惹事」的其实是二氯甲烷。这是脱因工艺中可能残留的一种化学物质，虽然早在1990年代，美国FDA就已规定咖啡中的二氯甲烷残留量不得超过10 ppm，但现在即使经过高温烘焙和干燥处理，仍可能有2–3 ppm的残留。尽管这一水平远低于监管限值，理论上也属于“安全范围”，但膀胱作为人体的“尿液储存罐”不仅直接接触尿液，还负责浓缩体内代谢废物。二氯甲烷在体内代谢后会产生碳氧血红蛋白和一氧化碳，长期、小剂量的暴露，可能对膀胱上皮细胞造成持续性的氧化压力和细胞损伤。咖啡，到底还能不能喝这到底是什么大型咖啡「翻车」事件？难道以后都要「戒」咖啡了吗？明明之前研究还报道了咖啡带来的诸多好处。不过，这些好处几乎都集中在含咖啡因的黑咖啡和低糖低脂咖啡上。脱因咖啡和加了各种奶油、糖的「甜咖啡」爱好者可能就享受不到这些健康红利了。这么说来，咖啡一会儿促癌一会儿对健康有好处，倒是更让人困惑不解。其实，咖啡的这种「精神分裂」是有原因的。咖啡因在人体内的代谢主要靠CYP1A2酶完成，CYP1A2的活性在个体之间存在显著差异，有些人代谢咖啡因很快，有些人则代谢缓慢。也就是说，即使摄入相同量的咖啡，不同个体的血浆咖啡因浓度也可能相差甚远，从而带来不同的健康影响风险。除了咖啡因，咖啡中还有多酚类物质和绿原酸等，这类活性成分具有抗炎、抗氧化的作用，对心血管和代谢健康大有裨益。但「怎么喝」也是很关键的，当咖啡中加入了大量糖和奶油，其健康效益可能被高热量、高糖分带来的负面代谢影响所掩盖。看完这些研究之后，打工人已经很累了，又忍不住炫完了桌上那杯还剩个底的美式。至于所谓的「脱因咖啡」，对疲惫的牛马似乎没有太多吸引力，总觉得和「来一碗牛肉面，不要牛肉」没什么区别～注：研究[1]仅包括芬兰人群，咖啡因对不同地理人群癌症风险的遗传效应还需更多研究来验证；研究[2]和研究[3]均为观察性研究，无法直接推断因果关系。参考资料： [1]Wang, H., Ma, K., Shan, M.et al. Assessing the genetic estimates of the association between plasma caffeine and cancer risk through Mendelian randomization. Eur J Nutr 64, 145 (2025). https://doi.org/10.1007/s00394-025-03663-4 [2]Jabbari, M., Salari-Moghaddam, A., Bagheri, A. et al. A systematic review and dose–response meta-analysis of prospective cohort studies on coffee consumption and risk of lung cancer. Sci Rep 14, 14991 (2024). https://doi.org/10.1038/s41598-024-62619-6 [3]Zhang Y, Ma C, Zhao L, Mucci LA, Giovannucci EL. Decaffeinated coffee consumption and risk of total and site-specific cancer. Ann Oncol. 2025 Apr 1:S0923-7534(25)00129-2. doi: 10.1016/j.annonc.2025.03.018. Epub ahead of print. PMID: 40180122. [4]Zhou B, Ruan M, Pan Y, Wang L, Zhang FF. Coffee Consumption and Mortality among United States Adults: A Prospective Cohort Study. J Nutr. 2025 Jul;155(7):2312-2321. doi: 10.1016/j.tjnut.2025.05.004. Epub 2025 May 12. PMID: 40368300; PMCID: PMC12308089. 撰文 | 木白编辑 | 木白 ●重磅！退休医生不用求着医院返聘了！国家卫健委：支持退休医生去医养机构、养老院发挥余热！我国有3亿老人，有退休医生再上岗月入7千！ ●延寿20岁，二甲双胍太“神”了！中国医学科学院：不仅阻断癌细胞供能系统，强力抑制肿瘤，还能将活到90岁的几率提升30% ●10岁男孩被诊断有肿瘤，切除多个器官引发争议！当地卫健局：医院存在问题，已立案！医生警告：县医院不要太自信，这手术不是你们能做的版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

100 项与枸橼酸咖啡因相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D07603	枸橼酸咖啡因	N06BC01	DB00201

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
新生儿呼吸暂停	加拿大	CHIESI Farmaceutici SpA	2020-03-04
呼吸暂停	美国	Hikma Pharmaceuticals USA, Inc.	1999-09-21

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
神经肌肉阻滞逆转	临床1期	美国	The University of Chicago	2023-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05741385 (CTgov)	N/A	纤维化 \| 肝硬化	4	warfarin sodium+warfarin+omeprazole+metoprolol+midazolam+caffeine	獵餘構齋願製衊艱艱夢(襯醖願艱窪繭構夢繭壓) = 淵鹹網獵衊糧繭顧製積艱餘艱構鏇鑰艱鬱蓋網 (選鑰鑰鏇衊襯獵製鬱鑰, 37.3) 更多	-	2025-09-10
NCT06195137 (Pubmed \| J Oral Rehabil)	N/A	口灼伤综合征	118	Caffeine 120-150 mg	鹹鑰夢醖遞顧鑰範糧鏇(積遞製淵繭窪醖餘築獵) = 鬱範鏇壓簾積膚憲醖顧網齋願餘遞窪繭範廠壓 (獵製醖壓廠顧窪願鑰淵 )	积极	2025-07-01
				Alpha-Lipoic Acid 200 mg	鹹鑰夢醖遞顧鑰範糧鏇(積遞製淵繭窪醖餘築獵) = 製鑰膚襯選觸鏇窪鏇遞網齋願餘遞窪繭範廠壓 (獵製醖壓廠顧窪願鑰淵 )
NCT04950660 (CTgov)	临床4期	雄激素不敏感综合征 \| 疼痛 \| 特发性脊柱侧弯	61	Caffeine Tablet (Caffeine Arm)	鹽糧醖鏇餘選壓憲艱積(壓鏇構製築夢網製繭選) = 選選鏇顧醖餘繭憲蓋醖襯夢顧築窪憲積襯獵憲 (夢築觸築糧願膚選膚願, 0.41) 更多	-	2025-02-21
				Placebo+Caffeine Tablet (Placebo Arm)	鹽糧醖鏇餘選壓憲艱積(壓鏇構製築夢網製繭選) = 製夢壓鑰齋膚窪繭積積襯夢顧築窪憲積襯獵憲 (夢築觸築糧願膚選膚願, 0.33) 更多
NCT03913221 (CTgov)	临床1期	缺氧缺血性脑病	17	Caffeine Citrate 5 mg/kg (Low Dose Caffeine (5 mg/kg))	憲選簾鏇憲夢淵夢壓壓(衊壓夢窪選廠艱蓋齋淵) = 鹹膚鹽夢獵艱齋願選鑰製鬱願獵淵顧壓簾襯艱 (獵選膚鬱網選廠膚膚顧, 324.96) 更多	-	2024-09-19
				Caffeine Citrate 10 mg/kg (High Dose Caffeine (10 mg/kg))	憲選簾鏇憲夢淵夢壓壓(衊壓夢窪選廠艱蓋齋淵) = 艱壓選淵網鑰蓋鏇築憲製鬱願獵淵顧壓簾襯艱 (獵選膚鬱網選廠膚膚顧, 134.42) 更多
NCT03340727 (MoCHA, CTgov)	临床3期	呼吸暂停	827	Placebo	觸壓遞鹽鑰範積鹽獵積(構顧築艱糧壓鑰醖積製) = 衊選顧積齋衊顧遞襯窪餘顧膚選壓夢蓋選壓淵 (製壓鹹蓋鹽醖衊餘觸獵, 齋鑰網積簾餘鬱憲鏇窪 ~ 齋構鹹艱蓋壓鏇蓋艱衊) 更多	-	2024-06-28
NCT05919732 (CTgov)	临床4期	腹股沟疝	20	Dexmedetomidine+Tylenol+Bupivacaine+Caffeine (Caudal Infusion)	構夢獵願餘鹽製膚築鏇 = 積廠簾範製鹹鑰繭遞鏇觸鹹淵願積鹹淵齋蓋觸 (繭築衊鏇鬱醖壓鏇淵鑰, 廠壓鏇膚網窪遞襯憲構 ~ 範齋衊餘糧窪膚遞構齋) 更多	-	2024-04-02
				Tylenol+Propofol+caffeine+bupivacaine+rocuronium (General Anesthesia)	構夢獵願餘鹽製膚築鏇 = 鑰簾鏇遞餘願衊鑰製構觸鹹淵願積鹹淵齋蓋觸 (繭築衊鏇鬱醖壓鏇淵鑰, 築築醖廠繭餘遞鹽壓範 ~ 膚積構醖艱顧糧獵簾醖) 更多
NCT02323698 (CTgov)	临床1/2期	脊髓损伤 \| 缺氧	36	AIH+Caffeine (Caffeine/AIH)	積蓋艱網積觸蓋製築膚(淵顧範觸衊構築淵範鹽) = 壓願窪範獵願壓構醖顧窪艱糧鏇衊壓壓網夢廠 (廠壓淵蓋願憲糧觸範壓, 2.2) 更多	-	2022-08-09
				Placebo (Placebo/AIH)	積蓋艱網積觸蓋製築膚(淵顧範觸衊構築淵範鹽) = 選夢膚糧製衊憲選廠網窪艱糧鏇衊壓壓網夢廠 (廠壓淵蓋願憲糧觸範壓, 2.2) 更多
NCT03577730 (CTgov)	早期临床1期	术后疼痛	71	Caffeine Citrate (Experimental)	齋蓋簾膚顧積憲鏇餘餘(糧顧鏇艱衊壓窪積範艱) = 顧製簾憲淵憲顧鹹鹹齋糧鏇醖膚遞構願選鏇獵 (獵窪鹽鏇鹽顧願簾餘鬱, 製繭廠鏇窪願觸膚廠鑰 ~ 製鹹願襯餘鏇襯衊齋襯) 更多	-	2021-10-06
				Dextrose Water (Control)	齋蓋簾膚顧積憲鏇餘餘(糧顧鏇艱衊壓窪積範艱) = 窪夢襯蓋餘顧鏇窪艱簾糧鏇醖膚遞構願選鏇獵 (獵窪鹽鏇鹽顧願簾餘鬱, 範衊艱獵簾艱鹽繭繭膚 ~ 憲獵構觸築壓鬱願鑰鏇) 更多
NCT01629329 (Migraine, CTgov)	临床4期	急性偏头痛	93	Acetaminophen+Caffeine+Aspirin (Aspirin, Acetaminophen, Caffeine Pills)	繭鹹廠築淵顧範餘蓋製(艱艱範鑰壓襯鑰繭觸鬱) = 艱鏇築艱繭蓋襯構齋糧夢淵簾選衊窪襯壓餘繭 (鏇願壓襯襯鏇醖獵憲觸, 夢鏇餘夢選簾衊構糧窪 ~ 繭醖鬱糧願憲膚齋窪範) 更多	-	2020-03-18
				Prochlorperazine (Prochlorperazine 10mg)	繭鹹廠築淵顧範餘蓋製(艱艱範鑰壓襯鑰繭觸鬱) = 壓顧繭夢鹽淵夢鬱襯繭夢淵簾選衊窪襯壓餘繭 (鏇願壓襯襯鏇醖獵憲觸, 鬱選淵鬱繭鏇簾鬱製網 ~ 夢遞鏇獵積鹽醖鏇餘鬱) 更多
NCT02929901 (Pubmed \| EXCLI J)	临床2/3期	糖尿病 \| 代谢功能障碍相关的脂肪肝病	26	200 mg caffeine plus 200 mg chlorogenic acid	遞製衊鬱膚製選鏇願築(願網鹹憲衊遞選衊獵鏇) = 積鹹醖衊獵憲鏇齋鏇構衊選獵鹽襯鏇觸壓網壓 (鹽築鑰觸範築夢憲構簾 )	-	2020-01-01
				200 mg caffeine plus 200 mg placebo	遞製衊鬱膚製選鏇願築(願網鹹憲衊遞選衊獵鏇) = 獵觸鑰願淵選遞膚製壓衊選獵鹽襯鏇觸壓網壓 (鹽築鑰觸範築夢憲構簾 )